CSPC Pharma stock sits 29.91 percent below HKD 12.67 target

Published on 10/17/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSPC Pharma trades 29.91 percent below a HKD 12.67 consensus target. CSPC Pharma stock last traded at HKD 8.88 on October 16, 2026, up 0.17 percent.

Analyst target and valuation

Simply Wall St listed a HKD 12.67 average target from 23 analysts on October 17, 2026.
CSPC Pharma traded at a P/E ratio of 11.62 on October 16, 2026.
CSPC Pharma stock last traded at HKD 8.88 on October 16, 2026 at 4:08 p.m. HKT, 0.17 percent above the prior close of October 15, 2026.
CSPC Pharma had a market capitalization of HKD 101.3 billion on October 16, 2026.

CSPC Pharma, HK1093012172, Illustration mit AI erstellt.

CSPC Pharma stock stood 29.91 percent below the HKD 12.67 average 12-month target listed by Simply Wall St on October 17, 2026. The consensus covered 23 analysts. CSPC Pharma stock last traded at HKD 8.88 on October 16, 2026 at 4:08 p.m. HKT, up 0.17 percent versus the HKD 8.87 prior close.

Valuation leaves room for comparison

The target comparison is only one part of the picture. CSPC Pharma carried a P/E ratio of 11.62 and a dividend yield of 0.03 percent on October 16, 2026. Its market capitalization was HKD 101.3 billion.

Price position on October 16

The stock closed its latest Hong Kong session at HKD 8.88, while the 52-week range ran from HKD 6.53 to HKD 10.96. The latest price was 18.98 percent below the 52-week high and 35.99 percent above the 52-week low. Trading volume reached 72,609,598 shares against an average volume of 86,480,966 shares, putting the session volume 16.04 percent below its average.

On October 16, 2026, CSPC disclosed a grant of awarded shares under its 2026 share award scheme through its investor-relations page at CSPC Pharma. The disclosure was separate from the valuation measures above.

Valuation and peer comparison

The valuation gap is visible against larger Hong Kong pharmaceutical groups, although the ratios are not directly interchangeable because the businesses and earnings profiles differ.

Comparison with peers

CSPC Pharma: plus 0.17 percent, P/E 11.62, market capitalization HKD 101.3 billion.

Sino Biopharmaceutical (HKEX, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion.

WuXi Biologics (HKEX, HKD): minus 0.90 percent, P/E 34.45, market capitalization HKD 198.4 billion.

Next dates remain unchanged

CSPC Pharma's investor-relations calendar lists the August 20, 2026 interim-results announcement and the May 28, 2026 shareholders meeting among its dated corporate events. The latest published calendar therefore supplies historical reference points rather than a future date for this report.

Stock position in context

The 11.62 P/E ratio, the 29.91 percent distance below the consensus target and the 18.98 percent gap to the 52-week high give investors three distinct measures for reading the HKD 8.88 price. The comparison with Sino Biopharmaceutical and WuXi Biologics also places CSPC Pharma's market value and valuation beside two Hong Kong-listed peers.

Market context: Current market reports.

More news and analyses on CSPC Pharma stock